The next generation instrument for screening hemoglobin disorders in newborns.
Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma
The strategic acquisition reinforces Sebia’s product portfolio & strategy in autoimmunity